Myriad Genetics (MYGN) experienced a significant 40.31% increase in after-hours trading on Tuesday, reaching $5.43.
This surge followed the release of the company’s Q2 2025 financial report, which revealed better-than-expected earnings of $0.05 per share and revenue of $213.1 million, surpassing estimates and showing year-over-year growth. Investors responded positively to the strong financial performance, driving the stock price higher after the market close.
